Related Experiment Videos
[Update of experience with prostatic cancer]
Harefuah
|March 1, 1993
Summary
Early diagnosis and radiotherapy improve survival for prostate cancer patients. Modern tools like PSA tests and transrectal ultrasonography are crucial for detecting prostate cancer early, enhancing treatment outcomes.
Area of Science:
- Urology
- Oncology
- Radiotherapy
Context:
- Retrospective analysis of 302 prostate cancer patients diagnosed between 1977-1982.
- Data updated to assess long-term survival outcomes.
- Includes various stages (A1-D) and differentiation grades of prostate adenocarcinoma.
Purpose:
- To evaluate the 10-year actuarial survival rates based on disease stage and differentiation.
- To compare the efficacy of radiotherapy alone versus combined radiotherapy and hormone therapy.
- To highlight the importance of early diagnosis in prostate cancer management.
Summary:
- Stage A1 prostate cancer patients (5%) not receiving treatment had 77% 10-year survival.
- Survival rates decreased significantly with advanced stages: A2 (75%), B (56%), C (38%), D (2%).
- Poorly differentiated adenocarcinoma showed a 10-year survival of 13% compared to 61% for well/moderately differentiated types.
Impact:
- Combined radiotherapy and hormone therapy yielded a 59% 10-year survival, significantly better than radiotherapy alone (19%).
- Radiotherapy is effective and potentially curative for pelvic-confined prostate cancer.
- Emphasizes the critical role of early detection using advanced diagnostic methods like transrectal ultrasonography and prostate-specific antigen (PSA) testing.